PDF(Pubmed)
Abstract：
BACKGROUND: The 17-gene Genomic Prostate Score (GPS) test has been clinically employed to predict adverse prognosis in prostate cancer. In this meta-analysis, we aimed to evaluate the prognostic value of the 17-gene GPS in patients with prostate cancer.
METHODS: Potentially relevant studies were obtained by searching PubMed, Web of Science, Embase databases from their inception to December 1, 2023. Studies were considered eligible if they evaluated the association of the 17-gene GPS with distant metastases, biochemical recurrence, or prostate cancer-specific mortality (PCSM) in prostate cancer patients. To estimate the prognostic value, we pooled the adjusted hazard ratio (HR) with 95% confidence intervals (CI) for the high versus low GPS group or per 20-unit increase in GPS.
RESULTS: Seven cohort studies that reported on 8 articles comprising 1,962 patients satisfied the eligibility criteria. Meta-analysis showed that per 20-unit increase in GPS was significantly associated with distant metastases (HR 2.99; 95% CI 1.97-4.53), biochemical recurrence (HR 2.18; 95% CI 1.64-2.89), and PCSM (HR 3.14; 95% CI 1.86-5.30). Moreover, patients with high GPS (> 40 points) had an increased risk of distant metastases (HR 5.22; 95% CI 3.72-7.31), biochemical recurrence (HR 4.41; 95% CI 2.29-8.49), and PCSM (HR 3.81; 95% CI 1.74-8.33) than those with low GPS (≤ 40 points).
CONCLUSIONS: A higher 17-gene GPS significantly predicts distant metastases, biochemical recurrence, and PCSM in men with clinically localized prostate cancer. However, large-scale multicenter prospective studies are necessary to further validate these findings.
METHODS: Potentially relevant studies were obtained by searching PubMed, Web of Science, Embase databases from their inception to December 1, 2023. Studies were considered eligible if they evaluated the association of the 17-gene GPS with distant metastases, biochemical recurrence, or prostate cancer-specific mortality (PCSM) in prostate cancer patients. To estimate the prognostic value, we pooled the adjusted hazard ratio (HR) with 95% confidence intervals (CI) for the high versus low GPS group or per 20-unit increase in GPS.
RESULTS: Seven cohort studies that reported on 8 articles comprising 1,962 patients satisfied the eligibility criteria. Meta-analysis showed that per 20-unit increase in GPS was significantly associated with distant metastases (HR 2.99; 95% CI 1.97-4.53), biochemical recurrence (HR 2.18; 95% CI 1.64-2.89), and PCSM (HR 3.14; 95% CI 1.86-5.30). Moreover, patients with high GPS (> 40 points) had an increased risk of distant metastases (HR 5.22; 95% CI 3.72-7.31), biochemical recurrence (HR 4.41; 95% CI 2.29-8.49), and PCSM (HR 3.81; 95% CI 1.74-8.33) than those with low GPS (≤ 40 points).
CONCLUSIONS: A higher 17-gene GPS significantly predicts distant metastases, biochemical recurrence, and PCSM in men with clinically localized prostate cancer. However, large-scale multicenter prospective studies are necessary to further validate these findings.
摘要：
背景：17基因基因组前列腺评分（GPS）测试已在临床上用于预测前列腺癌的不良预后。在这个荟萃分析中，我们旨在评估17基因GPS在前列腺癌患者中的预后价值.
方法：通过搜索PubMed，WebofScience,Embase数据库从成立到2023年12月1日。如果他们评估了17基因GPS与远处转移的关联，则认为这些研究是合格的。生化复发，或前列腺癌患者的前列腺癌特异性死亡率（PCSM）。为了估计预后价值，我们将高与低GPS组或每增加20个单位的GPS的校正风险比(HR)与95%置信区间(CI)合并.
结果：7项队列研究报告了8篇文章，包括1,962名患者，符合资格标准。Meta分析显示GPS每增加20个单位与远处转移显著相关(HR2.99;95%CI1.97-4.53),生化复发（HR2.18；95%CI1.64-2.89），和PCSM（HR3.14；95%CI1.86-5.30）。此外，高GPS(>40分)患者发生远处转移的风险增加(HR5.22;95%CI3.72-7.31),生化复发（HR4.41；95%CI2.29-8.49），和PCSM（HR3.81；95%CI1.74-8.33）比GPS低（≤40点）。
结论：较高的17基因GPS可显著预测远处转移，生化复发，和PCSM在男性临床局限性前列腺癌中的应用。然而,需要大规模多中心前瞻性研究来进一步验证这些发现.
方法：通过搜索PubMed，WebofScience,Embase数据库从成立到2023年12月1日。如果他们评估了17基因GPS与远处转移的关联，则认为这些研究是合格的。生化复发，或前列腺癌患者的前列腺癌特异性死亡率（PCSM）。为了估计预后价值，我们将高与低GPS组或每增加20个单位的GPS的校正风险比(HR)与95%置信区间(CI)合并.
结果：7项队列研究报告了8篇文章，包括1,962名患者，符合资格标准。Meta分析显示GPS每增加20个单位与远处转移显著相关(HR2.99;95%CI1.97-4.53),生化复发（HR2.18；95%CI1.64-2.89），和PCSM（HR3.14；95%CI1.86-5.30）。此外，高GPS(>40分)患者发生远处转移的风险增加(HR5.22;95%CI3.72-7.31),生化复发（HR4.41；95%CI2.29-8.49），和PCSM（HR3.81；95%CI1.74-8.33）比GPS低（≤40点）。
结论：较高的17基因GPS可显著预测远处转移，生化复发，和PCSM在男性临床局限性前列腺癌中的应用。然而,需要大规模多中心前瞻性研究来进一步验证这些发现.
